Characterization of cholyl-leu-val-phe-pheala-OH as an inhibitor of amyloid betapeptide polymerization

Amyloid

Volumn 8, Issue 4, 2001, Pages 231-241

  Findeis, M A ^a   Lee, J D ^a   Kelley, M ^a   Wakefield, J D ^a   Zhang, M H ^a   Chin, J ^a   Kubasek, W ^a   Molineaux, S M ^a  

^a Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

A beta; Aggregation; Amyloid; Beta peptide; Inhibition; Inhibitor; Polymerization

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; CHOLYLLEUCYLVALYLPHENYLALANYLPHENYLALANYLALANINE; MONOMERIC IONIC CONTRAST MEDIUM; OLIGOMER; PPI 368; PREALBUMIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; ELECTRON MICROSCOPY; FIBER; GEL FILTRATION; HUMAN; HUMAN CELL; NEUROTOXICITY; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0035676280     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120108993819     Document Type: Article

References (46)

1. Modified-peptide inhibitors of β-peptide polymerization
2. Discovery and characterization of peptidoorganic inhibitors of amyloid β-peptide polymerization
3. Design and testing of inhibitors of fibril formation
4. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4
5. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides
6. Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease
7. Arrest of beta-amyloid fibril formation by a pentapeptide ligand
8. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation
9. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
10. A strategy for designing inhibitors of beta-amyloid toxicity
11. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity
12. Alzheimer's disease: Genotypes, phenotypes, and treatments
13. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity
14. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red
15. Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease
16. Rapid, high-resolution HPLC separation of peptides using small particles at elevated temperatures
17. 2-Chlorotrityl chloride resin. Studies on anchoring of Fmocamino acids and peptide cleavage
18. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
19. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
20. Interspecies sequence variations affect the kinetics and thermodynamics of amyloid formation: Peptide models of pancreatic amyloid
21. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
22. Thioflavine T interaction with amyloid β-sheet structures
23. Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations
24. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death
25. Toxicity, of protein aggregates in PC 12 cells: 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide assay
26. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
27. Translating cell biology into therapeutic advances in Alzheimer's disease
28. Cognitive enhancement therapy for Alzheimer's disease. The way forward
29. Treatment of Alzheimer's disease
30. Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease
31. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
32. Familial amyloid polyneuropathy: New developments in genetics and treatment
33. Resolution of heart failure in patients with AL amyloidosis
34. Aggregation and disaggregation of senile plaques in Alzheimer disease
35. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
36. Immunologic treatment of Alzheimer's disease
37. Diffusible, nonfibrillar ligands derived from A beta1-42 are potent central nervous system neurotoxins
38. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
39. Amyloid beta-protein fibrillogenesis. Structure and biological activity, of protofibrillar intermediates
40. Assembly of A-beta amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease
41. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy
42. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein